Patent: 10,072,098
✉ Email this page to a colleague
Summary for Patent: 10,072,098
| Title: | Pseudomonas aeruginosa PCRV binding single variable domain antibodies |
| Abstract: | Polypeptides are provided that are capable of significantly inhibiting and/or neutralizing P aeruginosa. The polypeptides comprise two or more immunoglobulin single variable domains that are directed against the PcrV protein of P. aeruginosa, wherein the \"first\" immunoglobulin single variable domain and the \"second\" immunoglobulin single variable domain have different paratopes. |
| Inventor(s): | De Tavernier; Evelyn (Deurle, BE), Union; Ann (Aalter, BE), Dombrecht; Bruno (Heusden, BE), Hermans; Guy (Merelbeke, BE), Morizzo; Erika (Ghent, BE) |
| Assignee: | Ablynx N.V. (Ghent-Zwijnaarde, BE) |
| Application Number: | 14/382,027 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,072,098
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Grifols Therapeutics Llc | ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 | albumin (human) | For Injection | 101138 | October 21, 1942 | ⤷ Start Trial | 2033-03-04 |
| Takeda Pharmaceuticals U.s.a., Inc. | BUMINATE, FLEXBUMIN | albumin (human) | Injection | 101452 | March 03, 1954 | ⤷ Start Trial | 2033-03-04 |
| Csl Behring Ag | ALBURX | albumin (human) | Injection | 102366 | July 23, 1976 | ⤷ Start Trial | 2033-03-04 |
| Grifols Biologicals Llc | ALBUTEIN | albumin (human) | Injection | 102478 | August 15, 1978 | ⤷ Start Trial | 2033-03-04 |
| Grifols Biologicals Llc | ALBUTEIN | albumin (human) | Injection | 102478 | November 29, 2022 | ⤷ Start Trial | 2033-03-04 |
| Instituto Grifols, S.a. | HUMAN ALBUMIN GRIFOLS | albumin (human) | Injection | 103352 | February 17, 1995 | ⤷ Start Trial | 2033-03-04 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
